While the groundbreaking for Novartis’ new flagship manufacturing hub in North Carolina grabbed national headlines this week, the company confirmed that its massive $23 billion U.S. investment plan includes a crucial expansion of its existing facilities right here in New Jersey.
The Switzerland-based innovative medicines company, which maintains its U.S. subsidiary headquarters in East Hanover, is strategically building out its “coast-to-coast” manufacturing network. This plan ensures that all key medicines for U.S. patients are produced end-to-end domestically.
As part of this expansion, Novartis is investing in its existing New Jersey sites—including a radioligand therapy (RLT) manufacturing facility in Millburn and its Morris Plains cell therapy production site.
New Jersey remains central to Novartis’ production of highly complex, advanced therapies:
-
Radioligand Therapy (RLT) Expansion: The Millburn facility is one of the company’s existing U.S. sites producing Radioligand Therapies, a highly specialized form of precision medicine used to treat cancer. The planned expansion aims to strengthen capacity for these time-sensitive, life-saving treatments, complementing new RLT facilities planned for Florida and Texas, and an expanded site in Indiana.
-
Cell Therapy Production: The Morris Plains facility, which employs approximately 700 people, has been a key site for manufacturing groundbreaking cell and gene therapies since 2015.
The commitment to expand New Jersey’s manufacturing footprint ensures the state remains a critical component of the company’s ambitious goal to localize its entire supply chain.
The New Jersey expansion is part of a five-year, $23 billion investment by Novartis in its U.S. infrastructure. The overall plan, which was highlighted this week by the groundbreaking of the 700,000-square-foot flagship hub in North Carolina, includes:
-
Building six new manufacturing plants across the U.S.
-
Expanding three existing U.S. plants, including the site in Millburn, NJ.
-
Establishing a new $1.1 billion biomedical research hub in San Diego, CA.
The entire U.S. investment plan is expected to create thousands of new jobs nationwide, further solidifying the pharmaceutical industry’s long-term presence in the American market.
